Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer

The delivery of therapeutics through the circulatory system is one of the least arduous and less invasive interventions; however, this approach is hampered by low vascular density or permeability. In this study, by exploiting the ability of monocytes to actively penetrate into diseased sites, we des...

Full description

Saved in:
Bibliographic Details
Published inScience advances Vol. 7; no. 17
Main Authors Huang, San-Shan, Lee, Keng-Jung, Chen, Hung-Chih, Prajnamitra, Ray Putra, Hsu, Chia-Hsin, Jian, Cheng-Bang, Yu, Xu-En, Chueh, Di-Yen, Kuo, Chiung Wen, Chiang, Tsai-Chen, Choong, Oi Kuan, Huang, Shao-Chan, Beh, Chaw Yee, Chen, Li-Lun, Lai, James J, Chen, Peilin, Kamp, Timothy J, Tien, Yu-Wen, Lee, Hsien-Ming, Hsieh, Patrick Ching-Ho
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 01.04.2021
Subjects
Carcinoma, Pancreatic Ductal - pathology
Health and Medicine
Heart Diseases - metabolism
Humans
Life Sciences
Monocytes - metabolism
Pancreatic Neoplasms - drug therapy
Reperfusion Injury
SciAdv r-articles
Online AccessGet full text

Cover

More Information
Summary:The delivery of therapeutics through the circulatory system is one of the least arduous and less invasive interventions; however, this approach is hampered by low vascular density or permeability. In this study, by exploiting the ability of monocytes to actively penetrate into diseased sites, we designed aptamer-based lipid nanovectors that actively bind onto the surface of monocytes and are released upon reaching the diseased sites. Our method was thoroughly assessed through treating two of the top causes of death in the world, cardiac ischemia-reperfusion injury and pancreatic ductal adenocarcinoma with or without liver metastasis, and showed a significant increase in survival and healing with no toxicity to the liver and kidneys in either case, indicating the success and ubiquity of our platform. We believe that this system provides a new therapeutic method, which can potentially be adapted to treat a myriad of diseases that involve monocyte recruitment in their pathophysiology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
Present address: Department of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA.
ISSN:2375-2548
2375-2548
DOI:10.1126/sciadv.abf2400